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Syndrome X: An Abolormnalityali Epicardial
J
or Microvascular Coronary Circulation?
Bugiardini et al
. (I) have demonstrated that patients with syndrome
X do not exhibit disease confined solely to the coronary microcir-
culalion but are affected by a disorder involving the entire coronary
artery tree in vasomotion . They suggest further that, as a similar
diffuse abnormality can also be observed in some patients having
variant angina, patients with chest pain duc
.o abnormal diffuse
vasoconstriction of both coronary epicardial and resistance vessels
have a single pathogenetic entity . However, their work also points
to the microcirculation as the major culprit because the degree
of
epicardial constriction observed in their study was unlikely to
contribute to the resistance of the coronary flow in the absence of
atherosclerotic narrowing .
We (2) have previously reported the effect of hyperventilation
and mental stress on coronary blood flow in 29 patients with
syndrome X
. Coronary blood flow velocity was measured with an
intracoronary Doppler catheter positioned in the proximal left
anterior descending coronary artery . Syndrome X was defined as
typical angina] chest pain and a positive exercise test result in
patients with completely normal coronary angiograms . In these
patients, both hyperventilation and mental stress prouticed chest
pain that was associated with a significant reduction
in coronary
blood flow velocity in the absence of significant changes in the
epicardial coronary artery diameter . Our observations suggest
that
inappropriate small vessel constriction leads to a primary reduction
of coronary blood flow in these patients
.
Kaski et al . (3) have also shown previously that syndrome X
does not involve increased vasomotor tone of the larger epicardial
coronary arteries . These findings are consistent with the previous
suggestion (4,5)
that an abnormal tone of the prearteriolar coronary
vessels may be responsible for the impaired coronary flow reserve
found in patients with syndrome X
. The results of our study tend to
support this view but are in conflict with the epicardial responses
observed by Bugiardini et al . (I) .
This may support the hypothesis
put forward by Maseri et al
. (5) that an uneven distribution of small
vessel vasoconstrictor zone may explain the variety of vasomotor
responses in patients with syndrome X .
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Reply
Chauhan et al . (1) have correctly pointed out apparent discrepancies
in studies dealing with anginalike chest pain and normal coronary
angiograms . In their study . hyperventilation and mental stress
produced chest pain and a significant reduction in coronary blood
flow in the absence of significant changes in epicardial coronary
artery diameter . In our study we concurrently reported that a
coronary vasomotor disorder that implies hypersensitivity to vaso-
constrictive stimuli is present not only at the arteriolar level, but
.tlso in the entire coronary artery tree
. Such epicardial findings were
recently confirmed by McFadden et al . (2) . It is difficult to say that
the results of Chauhan et al . are surprising . Kaski et al
. (3) had made
similar observations . As previously suggested by Kern (4) . all of
these data support a heterogeneous subgrouping of patients with
angina and normal coronary angiograms. Studies examining the
endothelial function in these patients have not explained the variety
of vasomotor response . Quyyumi et al
. (5) reported that 10% of their
patients had severe diffuse epicardial constriction during intracoro-
nary infusion of acetylcholine S x l0' mol/liler, whereas 71 1/(
showed some degree of epicardial
asoconstriction but reduced
coronary blood flow, which implies changes at arteriolar levels . We
therefore believe that in some patients the functional abnormalities
may be exclusive to large or small arteries : in others, components of
the entire coronary tree may be involved, as our report indicates .
One point deserves further mention
. Central to our hypothesis is
the primary role of resistance vessels in the genesis of myocardial
ischemia even in the presence of diffuse vasoconstriction of epicar-
dial coronary arteries . Our data show that in these patients the
decrease in blood flow caused by hyperventilation is not prevented
by 0.3 mg of subl
;ngual nitroglycerin, which dilates epicardial
coronary arteries . A natural extension of this observation is the
belief that those patients with Prinzmetal's angina who exhibit
intense (>30 diameter reduction) and diffuse constriction of all
coronary artery branches have ischemia due to "spasm" of resis-
tance vessels, with large vessel "spasm" being irrelevant and
representing only a marker of the underlying pathophysiologic
condition .
In conclusion, more studies are clearly needed to clarify the
mechanism of angina in patients with angina and normal angio-
grams. Al present, "microvascular angina" (6) and "vasotonic
angina" (2) mast be considered descriptive categories referring .
respectively, to functional coronary abnormalities of the resistance
vessels and the entire coronary artery tree
. We hope that our work
will stimulate further investigation of this possibly common and
important manifestation of angina pectoris
.
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Safety of Placebo-Controlled Trials in
Vasospastic Angina
Chahine et a] . (1) recently reported the results of a randomized
placebo-controlled trial investigating the effects of floe long-acting
dihydropyridine calcium anisigoriml amlodyine in 52 patients with
vasospastic angina . Ali :ialiYnis were in an active phase of vial'iant
angina, with angiographically documented spasm of a major coro-
nary artery and a mean number of 12 anginal attacks/week . Never-
theless, they were randomized to take amlodipine "0 mg once daily)
or placebo for 4 weeks in double-blind conditions withou, any
background prophylactic treatment . During the 4 weeks of the
study, placebo-treated patients continued to suffer from a mean of
14 to 15 anginal attacks/week, whereas the rate was reduced to 5 to
6 attacks/week in am ;odipine-treated patients .
We (2,3) have previously argued that placebo-controlled trials
should be avoided in variant angina because, during the active phase
of this
syndrome, acute myocardial infarction and sudden death may
occur in up to 20% and 10% of patients, respectively, and calcium
antagonists have clearly been shown to prevent these major cardio-
vascular events (4,5) . Probably for this reason . placebo-controlled
trials are not even requested by the Food and Drug Administration
to support approval for vasospastic angina (particularly when a drug
has already been approved for stable effort angina) . The high
number of anginal attacks reported for 4 weeks by the placebo-
treated patients in the study of Chahine et a] . (1) reinforces our
arguments. In addition, 7 (26%) of their 27 placebo-treated patients
were withdrawn from the study because of "therapeutic failure ."
What actually happened to these patients was not specified by the
authors, although this information is of the greatest importance,
because such "therapeutic failures" may mean intolerable angina,
myocardial infarction or sudden death', in fact, two patients (8%) in
the amlodipine group were " . . . withdrawn from the study because
of therapeutic failure (one patient because of admission to the
hospital to rule out myocardial infarction and one as a result of
persistent intolerable angina)."
With regard to the efficacy of amlodipine, the authors conclude
that "amlodipine given once daily is efficacious . . . in the treatment
of vasospastic angina ." Although several studies in hypertension
and stable angina have shown the long duration of action of
amlodipine, the conclusion that once-daily amlodipine is aa effective
treatment for vasospastic angina is only partially supported by the
data of the Amlodipine Study 160 (1) . Although amlodipine-treated
patients experienced a reduction in the anginal attack rate from 12 to
5 attacks/week, the circadian distribution of these residual anginal
episodes is not described by the authors . In vasospastic angina,
anginal attacks are preferentiaHy grouped in the early morning
hours, and it is extremely important that any antianginal medication
be effective during this time (6)
. This is particularly true for
once-daily medications, which might lose efficacy toward the end of
the dosing interval .
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Reply
Ardissino and Savonitto primarily express their concern about
performing placebo-controlled trials in vasospastic angina, and once
more they recommend instead "active-controlled trials ." Although
it is understandable that one would be concerned about using
placebo in any patient with cardiac symptoms, there is a consensus
that this is still the best way to demonstrate efficacy and safety of
newer therapy . The CAST study (I) and its results represent the best
response to questions about the ethics of performing placebo-
controlled trials in cardiac patients .
In our opinion, the concerns of Ardissino and Savonitto about
the ethics of using placebo controls in our study are totally unjusti-
fied . We strongly feel that the benefits of our choice of protocol
clearly outweigh the small and acceptable risks . The duration of the
placebo phase in our study was short and patients were closely
monitored
. If there was any significant exacerbation of symptoms
characterized as therapeutic failure, the double-blind therapy
was
stopped and patients were placed on open therapy . Our patients
represented i rather low risk group
; 75% had angiographically
normal or near normal coronary arteries . No catastrophic event
occurred during the placebo phase of our study or in the half-dozen
or more placebo-controlled trials referenced in our study and the
letter of Ardissino and Savonitto . Patients were properly info( med
of the potential risks, and our protocol was approved independently
by the 15 different institutional review boards of the centers con-
tributing to the trial
. Further, the relative protective effects of the
calcium antagonists were observed in long-term open studies hill
were never proved by controlled trials
. To our knowledge, the Food
and Drug Administration considers approval of newer therapies for
vasospastic angina on the basis of at least one controlled trial (2) .
This singular requirement may be related more to the difficulty
of
finding enough patients to enroll than to ethical concerns .
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